Similar articles for PMID: 11038004

Year	Number of Results
1966	1
1969	1
1998	2
1999	1
2000	4
2001	4
2002	4
2003	5
2004	7
2005	1
2006	3
2007	4
2008	3
2009	1
2024	0

1

Enzyme inhibition as an aid to simplify pharmacokinetic measurements?

Tewson TJ. Tewson TJ. J Nucl Med. 2000 Oct;41(10):1725-6. J Nucl Med. 2000. PMID: 11038004 Free article. No abstract available.

2

Blocking catabolism with eniluracil enhances PET studies of 5-[18F]fluorouracil pharmacokinetics.

Bading JR, Alauddin MM, Fissekis JD, Shahinian AH, Joung J, Spector T, Conti PS. Bading JR, et al. J Nucl Med. 2000 Oct;41(10):1714-24. J Nucl Med. 2000. PMID: 11038003 Free article.

3

Extraction of 5-fluorouracil by tumor and liver: a noninvasive positron emission tomography study of patients with gastrointestinal cancer.

Aboagye EO, Saleem A, Cunningham VJ, Osman S, Price PM. Aboagye EO, et al. Cancer Res. 2001 Jul 1;61(13):4937-41. Cancer Res. 2001. PMID: 11431319

4

Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule.

Guo XD, Harold N, Saif MW, Schuler B, Szabo E, Hamilton JM, Monahan BP, Quinn MG, Cliatt J, Nguyen D, Grollman F, Thomas RR, McQuigan EA, Wilson R, Takimoto CH, Grem JL. Guo XD, et al. Cancer Chemother Pharmacol. 2003 Jul;52(1):79-85. doi: 10.1007/s00280-003-0613-0. Epub 2003 Apr 18. Cancer Chemother Pharmacol. 2003. PMID: 12707718 Clinical Trial.

5

A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005).

O'Donnell A, Punt CJ, Judson I, Van Maanen L, Suttle AB, Ertel P, Beale P. O'Donnell A, et al. Cancer Chemother Pharmacol. 2003 Jan;51(1):58-66. doi: 10.1007/s00280-002-0536-1. Epub 2002 Nov 20. Cancer Chemother Pharmacol. 2003. PMID: 12497207

6

[The uptake characteristics of 5-fluorouracil in the Caco-2 model system].

Chen J, Xu Z, Li Y. Chen J, et al. Yao Xue Xue Bao. 1998;33(3):222-5. Yao Xue Xue Bao. 1998. PMID: 11938968 Chinese.

7

Oral eniluracil/5-FU for advanced colon and breast carcinomas.

Benson AB 3rd. Benson AB 3rd. Oncology (Williston Park). 2001 Jan;15(1 Suppl 2):57-63; discussion 64. Oncology (Williston Park). 2001. PMID: 11219979 Review.

8

Sources of error in tissue and tumor measurements of 5-[18F]fluorouracil.

Harte RJ, Matthews JC, O'Reilly SM, Price PM. Harte RJ, et al. J Nucl Med. 1998 Aug;39(8):1370-6. J Nucl Med. 1998. PMID: 9708510 Free article.

9

Important role of the dihydrouracil/uracil ratio in marked interpatient variations of fluoropyrimidine pharmacokinetics and pharmacodynamics.

Jiang H, Lu J, Jiang J, Hu P. Jiang H, et al. J Clin Pharmacol. 2004 Nov;44(11):1260-72. doi: 10.1177/0091270004268911. J Clin Pharmacol. 2004. PMID: 15496644 Clinical Trial.

10

The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients.

Zhou ZW, Wang GQ, Wan de S, Lu ZH, Chen YB, Li S, Chen G, Pan ZZ. Zhou ZW, et al. Chemotherapy. 2007;53(2):127-31. doi: 10.1159/000099984. Epub 2007 Feb 16. Chemotherapy. 2007. PMID: 17308379 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

37 results

Results by year